Increasing pharmacological knowledge about human neurological and psychiatric disorders through functional neuroimaging and its application in drug discovery

被引:39
作者
Nathan, Pradeep J. [1 ,2 ,3 ]
Phan, K. Luan [4 ,5 ]
Harmer, Catherine J. [6 ]
Mehta, Mitul A. [7 ]
Bullmore, Edward T. [1 ,8 ]
机构
[1] Univ Cambridge, Dept Psychiat, Behav & Clin Neurosci Inst, Brain Mapping Unit, Cambridge CB2 1TN, England
[2] Monash Univ, Sch Psychol & Psychiat, Clayton, Vic 3800, Australia
[3] UCB Pharma, New Med, Brussels, Belgium
[4] Univ Illinois, Dept Psychiat, Chicago, IL 60612 USA
[5] Jesse Brown VA Med Ctr, Mental Hlth Serv Line, Chicago, IL USA
[6] Univ Oxford, Dept Psychiat, Oxford OX1 2JD, England
[7] Kings Coll London, Inst Psychiat, Dept Neuroimaging, London WC2R 2LS, England
[8] GlaxoSmithKline, GSK Clin Unit Cambridge, Cambridge, England
基金
英国医学研究理事会;
关键词
NK1 RECEPTOR ANTAGONISM; CUE-INDUCED ACTIVATION; BRAIN ACTIVATION; AMYGDALA REACTIVITY; ANTERIOR CINGULATE; PREFRONTAL CORTEX; ANXIETY DISORDER; NEURAL RESPONSE; SOCIAL SIGNALS; ALCOHOL CUES;
D O I
10.1016/j.coph.2013.11.009
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Functional imaging methods such as fMRI have been widely used to gain greater understanding of brain circuitry abnormalities in CNS disorders and their underlying neurochemical basis. Findings suggest that: (1) drugs with known clinical efficacy have consistent effects on disease relevant brain circuitry, (2) brain activation changes at baseline or early drug effects on brain activity can predict long-term efficacy; and (3) fMRI together with pharmacological challenges could serve as experimental models of disease phenotypes and be used for screening novel drugs. Together, these observations suggest that drug related modulation of disease relevant brain circuitry may serve as a promising biomarker/method for use in drug discovery to demonstrate target engagement, differential efficacy, dose-response relationships, and prediction of clinically relevant changes.
引用
收藏
页码:54 / 61
页数:8
相关论文
共 63 条
[1]   NMDA receptor function in large-scale anticorrelated neural systems with implications for cognition and schizophrenia [J].
Anticevic, Alan ;
Gancsos, Mark ;
Murray, John D. ;
Repovs, Grega ;
Driesen, Naomi R. ;
Ennis, Debra J. ;
Niciu, Mark J. ;
Morgan, Peter T. ;
Surti, Toral S. ;
Bloch, Michael H. ;
Ramani, Ramachandran ;
Smith, Mark A. ;
Wang, Xiao-Jing ;
Krystal, John H. ;
Corlett, Philip R. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (41) :16720-16725
[2]   Escitalopram effects on insula and amygdala BOLD activation during emotional processing [J].
Arce, Estibaliz ;
Simmons, Alan N. ;
Lovero, Kathryn L. ;
Stein, Murray B. ;
Paulus, Martin P. .
PSYCHOPHARMACOLOGY, 2008, 196 (04) :661-672
[3]   Pregabalin effects on neural response to emotional faces [J].
Aupperle, Robin L. ;
Tankersley, Dharol ;
Ravindran, Lakshmi N. ;
Flagan, Taru ;
Stein, Nathan R. ;
Stein, Murray B. ;
Paulus, Martin P. .
FRONTIERS IN HUMAN NEUROSCIENCE, 2012, 6
[4]   A role for fMRI in optimizing CNS drug development [J].
Borsook, D ;
Becerra, L ;
Hargreaves, R .
NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (05) :411-424
[5]   Determinants of real-world functional performance in schizophrenia subjects: Correlations with cognition, functional capacity, and symptoms [J].
Bowie, CR ;
Reichenberg, A ;
Patterson, TL ;
Heaton, RK ;
Harvey, PD .
AMERICAN JOURNAL OF PSYCHIATRY, 2006, 163 (03) :418-425
[6]   NK1 receptor antagonism and emotional processing in healthy volunteers [J].
Chandra, P. ;
Hafizi, S. ;
Massey-Chase, R. M. ;
Goodwin, G. M. ;
Cowen, P. J. ;
Harmer, C. J. .
JOURNAL OF PSYCHOPHARMACOLOGY, 2010, 24 (04) :481-487
[7]   Awake Rat Pharmacological Magnetic Resonance Imaging as a Translational Pharmacodynamic Biomarker: Metabotropic Glutamate 2/3 Agonist Modulation of Ketamine-Induced Blood Oxygenation Level Dependence Signals [J].
Chin, Chih-Liang ;
Upadhyay, Jaymin ;
Marek, Gerard J. ;
Baker, Scott J. ;
Zhang, Min ;
Mezler, Mario ;
Fox, Gerard B. ;
Day, Mark .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2011, 336 (03) :709-715
[8]   The age of anxiety: role of animal models of anxiolytic action in drug discovery [J].
Cryan, John F. ;
Sweeney, Fabian F. .
BRITISH JOURNAL OF PHARMACOLOGY, 2011, 164 (04) :1129-1161
[9]   Test-retest reliability of the BOLD pharmacological MRI response to ketamine in healthy volunteers [J].
De Simoni, S. ;
Schwarz, A. J. ;
O'Daly, O. G. ;
Marquand, A. F. ;
Brittain, C. ;
Gonzales, C. ;
Stephenson, S. ;
Williams, S. C. R. ;
Mehta, M. A. .
NEUROIMAGE, 2013, 64 :75-90
[10]   Glutamate and the neural basis of the subjective effects of ketamine [J].
Deakin, J. F. William ;
Lees, Jane ;
Mckie, Shane ;
Hallak, Jaime E. C. ;
Williams, Steve R. ;
Dursun, Serdar M. .
ARCHIVES OF GENERAL PSYCHIATRY, 2008, 65 (02) :154-164